Vous êtes sur la page 1sur 7

Breast

1. Hietala M, Sandberg T, Borg A, Olsson H, Jernstrom H. Testosterone levels in relation to oral


contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy
young women. Hum Reprod 2007;22(1):83-91.

2. Skold M, Ryden T, Samuelsson V, Bratt C, Ekblad L, Olsson H, et al. Regression analysis and
modelling of data acquisition for SELDI-TOF mass spectrometry. Bioinformatics 2007.

3. Brohet R, Goldgar D, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral
contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study
(IBCCS): A Report from Embrace, Genespo, Geo-Hebron, and the IBCCS Collaborating Group. J
Clin Oncol 2007;25(25 (Sept 1)):1-7.

4. Gunnarsson H, Jonsson G, Arason A, Agnarsson BA, Johannsson OT, Vallon-Christersson J, et


al.: Mapping of genomic aberrations using array-CGH of breast tumors from families with
germline mutations in BRCA1 and BRCA2 genes and high risk breast cancer families without
BRCA1/2 mutations. Proceedings of the American Association for Cancer Research Annual
Meeting 2007; 48:11.

5. Ekblad L, Baldetorp B, Ferno M, Olsson H, Bratt C. In-source decay causes artifacts in


SELDI-TOF MS spectra. J Proteome Res 2007;6(4):1609-14.

6. Ericson U, Sonestedt E, Gullberg B, Olsson H, Wirfält E. High folate intake is associated with
lower breast cancer incidence among postmenopausal women in the Malmö Diet and Cancer
Cohort. Am J Clinical Nutrition 2007;86(2):434-43.

7. Elsakov P, Foretova L, Goetz P, al. e. Discussion of the use of taxanes for treatment of breast
cancers in BRCA1 mutation carriers. Hereditary Cancer in Clinical Practice 2007;5(3):119-43.

8. Henningson M, Johansson U, Borg A, Olsson H, Jernstrom H. CYP17 genotype is associated


with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young
healthy women. Mol Hum Reprod 2007;13(4):231-6.

9. Rennstam K, Ringberg A, Ben-Dor A, Yakhini Z, Cunliffe H, Olsson H, et al.: A CGH-based


DNA copy number analysis of prophylactic breast tissue from BRCA1 mutation carriers
Oncogenomics 2007: Dissecting cancer through Genome Research 2007. Miami.

10. von Wachenfeldt A, Lindblom A, The South Swedish Oncogenetic Study Group, Grönberg H,
Einbeigi Z, Rosenquist R, et al. Breast Cancer Syndromes. A hypothesis-generating search for
new genetic breast cancer syndromes-a national study in 803 Swedish families. Hereditary
Cancer in Clinicl Practice 2007;5(1).

11. Hietala M, Olsson H, Jernstrom H. Prolactin levels, breast-feeding and milk production in a
cohort of young healthy women from high-risk breast cancer families: implications for breast
cancer risk. Familial Cancer 2008;7(3):221-28.
12. Saal L, Gruvberger-Saal S, Persson C, Lövgren K, Jumppanen M, Staaf J, et al. PTEN and
BRCA1 in Basal-like Breast Cancer. Nature Genetics 2008;40 (1)(Jan):102-7.

13. Carlsson A, Wingren C, Ingvarsson J, Ellmark, P., Baldetorp B, Fernö M, et al. Serum
proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J
Cancer 2008;44(3):472-80.

14. Olsson H, Luts L, Anderson H: Unilateral breast abnormalities and laterality of breast cancer-
a case only study AACR 2008.

15. Vallon-Christersson JL, Jonsson G, Ringner M, Arason A, Fagerholm R, Hegardt C, et al.:


97th Annual Meeting of the American-Association-for-Cancer-Research (AACR), April 01 -05,
2006, Washington, DC, USA 2007; 47:196.

16. Henningson M, Bageman E, Sandberg T, Borg A, Olsson H, Jernstrom H. Absence of the


common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than
among non-carriers from BRCA1 families. Fam Cancer 2007;6(4):445-52.

17. Kotsopoulos J, Lubinski J, Lynch H, al. e. Age at first birth and the risk of breast cancer in
BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment 2007;105:221-28.

18. Kotsopoulos J, Librach C, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, et al. Infertility,


treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2
mutations: a case control study. Cancer Causes and Control 2008;19:1111-19.

19. Olsson H, Magnusson S, Bladstrom A. Lower breast cancer survival in mothers of children
with a malignancy. Br J Cancer 2008;Jun3; 98(11):1876-8.

20. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral
contraceptives: collaborative reanalysis of data from 45 epidemiological studies
including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008;371:303-14.

21. Sonestedt E, Borgquist S, Ericson U, Gullberg B, Landberg G, Olsson H, et al. Plant foods
and breast cancer characterized by estrogen receptor a and ß status. observations from the
Malmö, Diet and Cancer cohort. Carcinogenesis 2008 Nov 29(11) 2203-9.

22. Welinder C, Jansson B, Fernö M, Olsson H, Baldetorp B. Expression of Helix poatia Lectin
Binding Glycoproteins in Women with Breast Cancer in Relationship to their blood group
phenotypes. J Proteome Res 2008(Nov 11).

23. Olsson H, Magnusson S, Borg Å, Kristoffersson U, Nilbert M, Wiebe T: Higher occurrence


of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes,
Oncol JC, ed. ASCO 2008:588S Abstract 11043.

24. Magnusson S, Borg Å, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence


of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.
Familial Cancer 2008;7(4 (May 15)):331-7.
25. Hedenfalk I, Ringberg A, Rennstam K, Isern A, Malina J, Cunliffe H, et al.: Histopathologic
findings and genetic instability in prophylactic mastectomy tissue from women with increased
hereditary risk of developing breast cancer2008; poster number 130.

26. Isern A, Malina J, Loman N, Olsson H, Ringberg A. Histopathological findings and oncologic
follow up after prophylactic mastectomy and immediate breast reconstruction in 100 patients
from families with hereditary breast cancer (in press). Eur J Surg Oncol 2008(April 21).

27. Sonestedt E, Pettersson U, Gullberg B, Olsson H, Wirfält E. Do hetereocyclic amines and


omega-6 polyunsaturated fatty acids contribute to the incidence of breast cancer in
postmenopausal women of the Malmö Diet and Cancer Cohort. Int J Cancer 2008;123 (7)(Oct
1):1637-43.

28. Sonestedt E, Borgkvist S, Pettersson U, Gullberg B, Olsson H, Adelercreutz H, et al.


Enterolactone is differently associated with estrogen receptor β positive and negative breast
cancer in the Malmö Diet and Cancer study . Cancer Epidemiology, Biomarkers and Prevention
2008;17(11):3241-51.

29. Jernstrom H, Henningson M, Johansson U, Olsson H. Coffee intake and CYP1A2*1F


genotype predicts breast volumes in young women (submitted). Br J Cancer 2008;99(9)(Nov
4):1534-38.

30. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, et al.
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1
and BRCA2 mutation carriers. Am J Hum Genet 2008;82(4):937-48.

31. Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, et al. No evidence
that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat 2008

32, Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The
BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and
extensions. Br J Cancer 2008;98(8):1457-66.

33. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The
BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and
extensions. Br J Cancer 2008;98(12):2015.

34. Rennstam K, Ringberg A, Cunliffe H, Olsson H, Landberg G, Hedenfalk I. Genomic


alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be
caused by BRCA1 haploinsufficiency (submitted) 2009.

35. Ericson U, Sonestedt E, Sjöholm M, Gullberg B, Carlson J, Olsson H, et al. High folate intake
in carriers of low MTHFR enzyme activity alleles is linked to reduced breast cancer incidence (jn
press). Cancer Epidemiology and Biomarkers Prev 2009 April 18(4), 1101-10.

36. Ericson U, Ivarsson M, Sonestedt E, Gullberg B, Carlson J, Olsson H, et al. Increased breast
cancer risk at high plasma folate levels among methylenetetrahydrofolate reductase 677T carriers.
(submitted) 2009.
37. Olsson H: Lobular carcinoma as a possible candidate phenotype for recessively inherited
breast cancer, Research C, ed. 31st Annual San Antonio Breast Cancer Sympoium Dec 10-14,
2008 San Antonio TX 2009; 89:119S-19S.

38. Broberg K, Huyn E, Schläwicke Engström K, Björk J, Ingvar C, Albin M, et al. Association
between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer (in press). BMC Canceer
2009.

39. CIMBA. No Association of the variants CASP8 D302H and CASP10 V410I with Breast
Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (manuscript)

40. Cederfur C, Fernö M, Olsson H, Leffler H. Increase of galectin-1 serum glycoprotein ligands
in breast cancer patients (submitted)

41. Brohet R, Andrieu N, Goldgar D, Antoniou AC, Chang-Claude J, Easton DF, et al. Hormone
replacement therapy and risk of breast cancer in the International BRCA1/2 Carrier Cohort Study
(IBCCS).

42. Wirfält E, Li C, Manjer J, Gullberg B, Ericson U, Sonestedt E, Olsson H. Food sources of fat
and sex hormone receptor defined breast cancer in the Malmö Diet and Cancer (MDC) cohort
(submitted)

43. Ellberg C, Jönsson G, Olsson H. Family history, mode of inheritance, germ line mutation
status, histopathology, risk factors and prognosis - Can a phenotype for recessive inheritance be
defined? (submitted)
.

44. Luts L, Johannsson O, Olsson H. Breast cancer in a multi cancer setting. A role for
parathyroid adenoma in a population based cancer registry study in Sweden. (submitted)

45. Sonestedt E, Ivarsson M, Harlid S, Ericson U, Gullberg B, Carlson J, et al. The protective
association of high plasma enterolactone with breast cancer is reasonably robust in women with
polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009;139(5):993-1001.

46. Isern A, Loman N, Tengrup I, Olsson H, Ringberg A. Aesthetic outcome, patient satisfaction
and quality of life in high-risk patients operated with prophylactic mastectomy and immediate
breast construction (submitted). J Plastic Reconstructive and Aesthetic Surgery
2008;61(10):1177-87.

Melanoma

1. Blum A, Ingvar C, Avramidis M, von Kannen A, Menzies S, Olsson H, et al. Time to diagnosis
of melanoma-same trend in different continents. Journal of Cutaneous Medicine and Surgery-
Basic/Clinical Science 2007;11(4 (Jul-Aug)):137-44.

2. Broberg K, Gustafsson C, Höglund M, Björk J, Ingvar C, Albin M, Olsson H.. Genetic


variation in the homologous recombination-associated gene RMI1 impacts cancer susceptibility.
Cancer Letter 2007;258((1) Dec 8):38-44.

3. Goldstein A, Chan M, Harland M, al. e. Features associated with germline CDKN2A


mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet
2007;44(2):99-106.

4. Brown KM, MacGregor S, Montgomery G, Craig DW, Zhao ZZ, Iyadurai K, et al. Common
sequence variants on 20q11.22 confer melanoma susceptibility . Nature Genetics 2008;40(7)(Jul
18):838-40.

5. Nielsen K, Ingvar C, Måsbäck A, Borg A, Sandberg T, Olsson H. Confirmed cancer trends in


families of patients with multiple cancers including cutaneous melanoma. Br J Dermatology
2008;158(2 (Feb)):429-31.

6. Backenhorn K, Staaf J, Måsbäck A, Olsson H, Ingvar C, Vallon-Christersson J, et al. Clonal


Selection in the Metastatic Process of Melanoma; an Epigenomic and Genomic Study (submitted)
2008.

7. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, et al. A novel 9p21 locus
and two pigmentation-associated regions contribute independently to melanoma risk in
populations of European ancestry (submitted Nature Genetics) 2009.

8. Chang Y-m, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman W, et al. A pooled
analyses of sun exposure and melanoma risk. A pooled analysis of 5700 cases and 7215 controls.
Int J Cancer 2009(April 8).

9. Chang Y-m, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, et al. A
Pooled Analysis of Melanocytic Naevus Phenotype and the Risk of Cutaneous Melanoma . Int J
Cancer 2009;124(2)(2):420-28.

10. Leachman S, Carucci J, Kohlmann W, Banks K, Asgari M, Bergman W, et al. Evidence-Based


Selection of Familial Melanoma Patients for Genetic Assessment (in press). The Journal of
American Academy Dermatology 2009.

11. Nielsen K, Måsbäck A, Backenhorn K, Jönsson G, Borg A, Güner N, Olsson H, Ingvar C.


CDKN2A mutation carriers in Sweden do not show a distinct phenotype (in press). Br J
Dermatology 2009.

12. Broberg K, Huyn E, Schläwicke Engström K, Björk J, Ingvar C, Albin M, Olsson H, Höglund
M. Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer (in
press). BMC Canceer 2009.
Ovary
1. McLaughlin J, Risch H, Lubinski J, al. e. Reproductive risk factors for ovarian cancer in
carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncology 2007;8(1):5-6.

2. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral
contraceptives: collaborative reanalysis of data from 45 epidemiological studies
including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008;371:303-14.

3. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA
model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer
2008;98(12):2015.

4. Antoniou A, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al. Reproductive


and hormonal factors, and ovarian cancer risk among BRCA1 and BRCA2 mutation carriers:
results from the International BRCA1/2 Carrier Cohort Study . Cancer Epidemiology and
Biomarkers 2009(Feb 3).

Prostate

1. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective study on dietary fat


and incidence of prostate cancer. Cancer Causes and Control 2007;10(Dec 18):1107-21.

2. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective study on body size,


body composition, diabetes and prostate cancer (in press). Br J Cancer 2009.

3. Åhsberg K, Olsson H, Stael von Holsten C. Increased mortality in prostate carcinoma and
smoking related disease after Parietal Cell Vagotomy (submitted)2008.

Annat
1. Ahrens W, Timmer A, Vyberg M, Fletcher T, Guenel P, Merler E, et al. Risk factors for
extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: Results from a
European multicentre case-control studyEur J. Eur J Gastroenterol Hepatol 2007;19(8):623-30.

2. Lindqvist PG, Epstein E, Bladstrom A, Olsson H. The relation between venous


thromboembolism and lifestyle factors - a report from the large prospective MISS study.
Thrombosis Research 2007;119:S110-S10.

3. Ahrens W, Mambetova C, Bourdon-Raverdy N, Llopis-González A, Guénel P, Hardell L, et al.


Occupational exposure to endocrine disrupting compounds and biliary tract cancer in men.
Results from a European multi-center case-control study. Scand J work Environ Health
2007;33(5):387-96.
4. Moll U, Landin-Olsson M, Olsson H. Pregnancies in prediabetic women. Diabetologia
2008;51(Suppl 1):S467-68 (abstract 1150).

5. Åhsberg K, Olsson H, Stael von Holsten C. Increased mortality in prostate carcinoma and
smoking related disease after Parietal Cell Vagotomy (submitted)2008.

6. Lindqvist P, Epstein E, Bladstrom A, Olsson H. The relation between venous


thromboembolism and life style factors-a report from the large prospective MISS study. Br J
Hematology 2009;144(2)(Jan):230-40.

7. Epstein E, Geppert B, Lindqvist P, Olsson H. A population-based cohort study on lifestyle


factors and endometrial cancer in Southern Sweden (submitted) 2009.

8. Epstein E, Lindqvist P, Olsson H. A population-based cohort study on the use of HRT and
endometrial cancer in southern Sweden (in press). Int J Cancer 2009.

9. Lindqvist P, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous
thrombotic events? −a D-lightful hypothesis . Journal of Thrombosis and Hemostasis
2009;7(4):605-10.

10. Olsson H, Attner B, Noreen D, Lithman T: Comorbidity prior to diagnosis in patients with
common cancer diagnoses, ASCO, ed. ASCO 2009 2009.

Childhood cancer
1. Olsson H, Magnusson S, Bladstrom A. Lower breast cancer survival in mothers of children
with a malignancy. Br J Cancer 2008;Jun3; 98(11):1876-8.

2. Olsson H, Magnusson S, Borg Å, Kristoffersson U, Nilbert M, Wiebe T: Higher occurrence of


childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes,
Oncol JC, ed. ASCO 2008:588S Abstract 11043.

3. Magnusson S, Borg Å, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of


childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes.
Familial Cancer 2008;7(4 (May 15)):331-7.

4. Magnusson S, Wiebe T, Jernström H, Kristoffersson U, Olsson H. High prevalence of family


history of cancer for Li-Fraumeni associated childhood tumours.A population based cancer
registry study. AACR abstract 3042 Proceedings vol 50 April 2009.